| Document |
Document Title |
|
WO/2019/055687A1 |
In one aspect, the disclosure relates to methods and compositions for treatment of cancer cachexia. In a further aspect, the composition is a pharmaceutical composition comprising a class l/IIB HDAC inhibitor and an androgen. In a still ...
|
|
WO/2019/055536A1 |
The present invention features compositions and methods that enhance cell extravasation and/or muscle cell fusion, and methods for identifying genes that enhance or inhibit extravasation and muscle cell fusion. One aspect of the present ...
|
|
WO/2019/054427A1 |
The present invention addresses the problem of providing a compound having an anti-inflammatory effect, a pharmacologically acceptable salt thereof, etc. The means for solution according to the present invention is a compound represented...
|
|
WO/2019/050923A1 |
The disclosure is directed to methods of treating subjects exposed to nerve agents with dantrolene, or a pharmaceutically acceptable salt thereof.
|
|
WO/2019/046903A1 |
The present disclosure provides a method of increasing muscle mass in a subject, the method comprising administering to the subject follistatin or a functional fragment thereof for a period of time and in an amount sufficient to effect a...
|
|
WO/2019/046251A1 |
The disclosure is directed to pharmaceutical compositions comprising of Tizanidine or a pharmaceutically acceptable salt thereof which controllably modulate the onset of at least one secondary effect associated with Tizanidine administra...
|
|
WO/2019/044788A1 |
The purpose of the present invention is to provide a topical dermatological composition capable of easily improving the body's ability to balance for ordinary non-athletes who do not actively perform everyday exercise, such as housewives...
|
|
WO/2019/044894A1 |
The present invention addresses the problem of providing a compound having strong conjugating activity with respect to a modified collagen, a use of the compound as a modified collagen test drug and research reagent, and a composition co...
|
|
WO/2019/041361A1 |
A compound of Formula (I), pharmaceutically acceptable salts thereof, and individual enantiomers or diastereomers thereof are disclosed. Compositions and methods useful for treatment or suppression of diseases, developmental delays and s...
|
|
WO/2019/044964A1 |
The present invention provides an exercise efficiency-improving composition, a fatigue-reducing composition, and a dynamic visual acuity-improving composition characterized by containing a kaempferol analog.
|
|
WO/2019/035405A1 |
Provided is a nonaqueous carbon dioxide external preparation in single dosage form, the external preparation comprising a paste base, carbonate, an acid and/or a substance which produces an acid by hydrolysis, and alcohol. Merely by bein...
|
|
WO/2019/034059A1 |
The present invention relates to a compound and the application thereof in treating inflammation or inflammation-related diseases, and more specifically to a compound UTLOH combination. Said compound effectively inhibits the level of LPS...
|
|
WO/2019/036267A1 |
Disclosed herein are methods for increasing circulating mesenchymal stem cells by administering a compound having the general formula 1 as defined herein, or a pharmaceutically acceptable salt thereof.
|
|
WO/2019/031425A1 |
The present invention mainly addresses the problem of providing a novel therapeutic agent for a motor neuron disease. Provided are: a therapeutic agent for a motor neuron disease which is characterized by comprising, as an active ingredi...
|
|
WO/2019/031442A1 |
Provided is a blood flow improver which is safe and has a mild action. This blood flow improver comprises S-1-propenylcysteine or a salt thereof as an active ingredient.
|
|
WO/2019/031495A1 |
The present invention addresses the problem of providing a drug which is highly stable and which contains a pyrazolone derivative such as edaravone, but does not contain sodium bisulfite. The present invention provides a drug which is de...
|
|
WO/2019/026930A1 |
The present invention provides a food composition for increasing muscle mass, muscle mass increasing agent, therapeutic agent for locomotive syndrome, therapeutic agent for sarcopenia, exercise function maintenance agent, muscle atrophy-...
|
|
WO/2019/026302A1 |
An agonist of 67 kDa laminin receptor, said agonist comprising as an active ingredient oolong tea polymerized polyphenols or a derivative thereof.
|
|
WO/2019/025474A1 |
The present invention relates to modulators of at least one endocannabinoid system component for use in i) the prevention and/or treatment of muscular dystrophy (MD) cardiomyopathy or other cardiomyopathies, and to pharmaceutical composi...
|
|
WO/2019/021059A1 |
The present disclosure provides a compound of formula (I): or a pharmaceutically acceptable salt thereof, and its therapeutic uses for activating a growth factor pathway, promoting wound healing, promoting tissue repair, and treating hea...
|
|
WO/2019/022216A1 |
The purpose of the present invention is to provide an amino acid composition having the novel, heretofore uninvestigated use of improving muscle strength with reference to a healthy state in which exhaustion does not occur. The present i...
|
|
WO/2019/021024A1 |
A method of treating lower limb spasticity in a subject, particularly one which is 18 years of age or under, comprising administering to the subject an effective amount of botulinum neurotoxin. A composition for use in treating lower lim...
|
|
WO/2019/021135A1 |
Composition for promoting mitochondrial biogenesis and improving mitochondrial function in a subject, the composition comprising an active agent, said active agent containing the amino acids leucine, isoleucine, valine, threonine, lysine...
|
|
WO/2019/022219A1 |
The purpose of the present invention is to provide a novel amino acid composition which can promote secretion of adrenaline and/or noradrenalin. The present invention relates to a noradrenaline secretion promoting amino acid composition ...
|
|
WO/2019/014772A1 |
The present invention relates to a therapeutic antisense oligonucleotide which binds to exon 51 of the human dystrophin pre-mRNA to induce exon skipping, and conjugates and compositions thereof for the treatment of DMD.
|
|
WO/2019/014774A1 |
In one aspect, a method of preconditioning stem cells comprising exposing stem cells to low dose radiation (LDR) is provided. In another aspect, a population of preconditioned stem cells is provided, wherein the population of 5 precondit...
|
|
WO/2019/016505A1 |
The present invention relates to the use of 2-chloro-2'-deoxyadenosine, hereinafter referred to as cladribine, or a pharmaceutically acceptable salt thereof, for treating or ameliorating an autoimmune, neuromuscular disorder, e.g. the au...
|
|
WO/2019/017338A1 |
Provided is a novel peptide. This peptide contains the amino acid sequence represented by SEQ ID NO: 18 and binds to an active protease, but does not bind to a precursor protease.
|
|
WO/2019/014300A1 |
The present invention provides compounds of Formula (I): Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitor...
|
|
WO/2019/014303A1 |
The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This inve...
|
|
WO/2019/011167A1 |
The invention relates to the field of biological medicines, in particular to a bispecific recombinant protein, a nucleic acid molecule for encoding the bispecific recombinant protein, a preparation method thereof, the use of the recombin...
|
|
WO/2019/014308A1 |
The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically-acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This inve...
|
|
WO/2018/041942A9 |
Embodiments of the invention are directed to new polymer linked multimeric guanosine-3', 5'-cyclic monophosphate (cGMP) analogues that modulate the cGMP-signaling system, preferably having activating properties, and more preferably being...
|
|
WO/2019/007991A1 |
The present disclosure relates to a MTMR2-S polypeptide, or a nucleic acid sequence producing or encoding said MTMR2-S polypeptide, for a use in the treatment of a disease or disorder associated with MTM1 mutation or deficiency. The pres...
|
|
WO/2019/006690A1 |
Provided are a polypeptide pharmaceutically acceptable salt and a pharmaceutical composition thereof, said polypeptide containing an amino acid sequence YEKLLDTEI or functional variants thereof.
|
|
WO/2019/005685A1 |
A method for treating a neurodegenerative disease or an inflammatory disorder in a subject, comprising administering to the subject in need thereof, a compound, or a pharmaceutically acceptable salt thereof, of formula II: wherein each o...
|
|
WO/2019/003104A1 |
The disclosure relates to novel uses and methods for preventing and/or treating urinary incontinence, which employ a therapeutically effective amount of an ActRII receptor antagonist, e.g., an ActRII receptor binding molecule, e.g., an A...
|
|
WO/2019/002875A1 |
The invention relates to improvements in drug delivery and to the use of Cell Penetrating Agents (CPA's) or Cell Penetrating Peptides (CPP's) which have been stabilized by, for example: i) stapling two amino acids to form Stapled CPP's (...
|
|
WO/2018/236698A1 |
A pharmaceutically acceptable transdermal composition for the treatment of patients with musculoskeletal connective tissue fibrosis or a disorder including Dupuytren's Contracture, Peyronie's disease, Ledderhose disease, or Knuckle Pads,...
|
|
WO/2018/234284A1 |
The invention relates to compound of formula (I) wherein R1 to R3 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.
|
|
WO/2018/232735A1 |
Provided is use of regulator in preparation of a medicament for regulating at least one of the following, wherein the regulator is used for activating or inhibiting Piezo: blood vessel development; blood pressure regulation; red blood ce...
|
|
WO/2018/236186A1 |
The present invention relates to a pharmaceutical composition containing a sesquiterpene derivative or a pharmaceutically acceptable salt thereof as an active ingredient for the prevention or treatment of muscle diseases.
|
|
WO/2018/235899A1 |
Provided is a method for culturing muscle stem cells while maintaining the undifferentiated properties of the cells. More specifically, muscle stem cells can be cultured while maintaining the undifferentiated properties of the cells by c...
|
|
WO/2018/230535A1 |
The present invention provides a skeletal muscle injury repair accelerator which contains, as an active ingredient: at least one selected from among (1) a peptide having the amino acid sequence represented by SEQ ID NO: 1, (2) a peptide ...
|
|
WO/2018/229629A1 |
A compound of formula (I) wherein R1, R2, R3, R4, X, Y, and A are as defined herein. The compounds of the present invention are inhibitors of hematopoietic prostaglandin D synthase (H-PGDS) and can be useful in the treatment of Duchenne ...
|
|
WO/2018/225673A1 |
Disclosed are: a method for manufacturing a therapeutic composition containing mammalian cells, said method comprising dispersing the mammalian cells in an aqueous glucose solution having a concentration of about 3-10% or Ringer's acetat...
|
|
WO/2018/224636A1 |
The present invention relates to the field of muscle pathologies, more particularly to the field of diseases where skeletal muscle wasting occurs. The invention provides the use of inhibitors of glutamine dehydrogenase for the regenerati...
|
|
WO/2018/221521A1 |
The present invention provides an anti-IGF-I receptor antibody that binds specifically to an IGF-I receptor of a vertebrate and has the proliferation-inducing activity of a vertebrate-derived cell, or a fragment thereof, or derivatives o...
|
|
WO/2018/221543A1 |
The present invention provides: an I-type crystal of (E)-2-(7-trifluoromethyl chromane-4-ylidene)-N-((7R)-7-hydroxy-5,6,7,8-tetrahydronaph
thalene-1-yl)acetamide having an excellent TRPV1 antagonistic activity; a medication and a medicat...
|
|
WO/2018/221679A1 |
This 6H-thieno[2,3-e][1,2,4]triazolo[3,4-c][1,2,4]triazepine derivative or a salt thereof has BRD4 inhibitory activity and is therefore useful as a drug, especially as an agent to prevent and/or treat diseases involving BRD4.
|
